Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2009

View Archived Issues

Novel P2X7 receptor antagonists jointly discovered by AMRI and Schering-Plough researchers

Recent Roche patent reports new antipsychotic tachykinin NK3 receptor antagonists

Kyorin scientists describe new antibacterial mutilin derivatives

Novel mGluR5 receptor modulators with antipsychotic properties developed at GSK

Four Novartis medicines approved in a single day in Japan

Celldex licenses cholera and ETEC vaccine programs to Vaccine Technologies

Alexza initiates phase IIb clinical trial of Staccato loxapine in migraine

S*BIO grants worldwide exclusive license to Tragara to develop and commercialize SB-1317

Ablynx transfers in-house bone disorder R&D program with Procter & Gamble

3SBio files for approval in China for TPIAO label extension in ITP

Clinuvel reports positive phase III interim results for afamelanotide in EPP

European marketing authorization application for Flutiform delayed

Opexa provides update on pipeline developments

Xoma provides guidance update for 2008

Parkinson's disease drug Trerief obtains marketing approval in Japan

Recalbon/Bonoteo tablets approved in Japan for osteoporosis treatment

Bristol-Myers Squibb receives approval in Japan for Sprycel

Remitch approved in Japan for improvement of pruritus in hemodialysis patients

Merck & Co. divulge new gamma-secretase modulators for Alzheimer's disease

AVI reports positive results from phase I trial of AVI-4658 for DMD

Ecard approved in Japan for hypertension

RegeneRx presents update on clinical development of RGN-259 for nonhealing corneal ulcers

Aradigm reports positive results from phase II study of ILCH in bronchiectasis

Improved cyclin-dependent kinase inhibitor developed at Greenpharma

Vitamin effect on homocystine levels does not affect Abeta levels in stroke patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...